论文部分内容阅读
目的观察美罗华联合CHOP方案治疗弥漫性大B细胞淋巴瘤的疗效及不良反应。方法 48例CD20阳性的弥漫性大B细胞淋巴瘤患者,随机分为观察组和对照组,每组24例。观察组采用美罗华联合CHOP方案化疗,对照组单用CHOP方案化疗。全部患者完成6个周期化疗后评价疗效。结果观察组和对照组的总有效率分别为91.7%(22/24)和66.7%(16/24),1年总生存率(OS)分别为95.8%和74.7%,3年OS分别为83.3%和50.0%,1年无进展生存率(PFS)分别为82.6%和57.3%,3年PFS分别为62.8%和37.2%,以上两组比较差异均有统计学意义(P<0.05)。两组患者的不良反应主要为胃肠道反应、骨髓抑制和输液相关不良反应。除畏寒、发热外,其余不良反应的发生率差异均无统计学意义(P>0.05)。结论美罗华联合CHOP方案治疗弥漫性大B细胞淋巴瘤疗效较好,未增加化疗毒性,安全性好,值得临床推广应用。
Objective To observe the efficacy and side effects of rituximab combined with CHOP regimen in the treatment of diffuse large B cell lymphoma. Methods 48 cases of CD20-positive patients with diffuse large B-cell lymphoma were randomly divided into observation group and control group, 24 cases in each group. The observation group was treated with rituximab combined with CHOP chemotherapy and the control group with CHOP chemotherapy alone. All patients to complete the evaluation of 6 cycles of chemotherapy efficacy. Results The total effective rates of the observation group and the control group were 91.7% (22/24) and 66.7% (16/24), respectively. The 1-year overall survival rates were 95.8% and 74.7%, respectively. The 3-year OS was 83.3 (PFS) were 82.6% and 57.3% respectively, PFS was 62.8% and 37.2% at 3 years respectively. The difference between the two groups was statistically significant (P <0.05). Adverse reactions in both groups were mainly gastrointestinal reactions, bone marrow suppression and infusion-related adverse reactions. In addition to chills, fever, the incidence of other adverse reactions were no significant difference (P> 0.05). Conclusion Rituximab combined with CHOP regimen is effective in treating diffuse large B cell lymphoma without any increase in chemotherapy toxicity and safety, which is worthy of clinical application.